A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
← catalyst calendarNCT06025578 · readout in 494 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,057estimated
Sites
459
Countries
Argentina, Australia, Austria +32
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-25 | actual | When the study began enrolling |
| Primary completion | 2027-12-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-27 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Progressive Pulmonary Fibrosis
Interventions
- Drug: BMS-986278
- Drug: BMS-986278 Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of participants that experience spontaneous syncopal events
measured At approximately 4 weeks
Absolute change from baseline in forced vital capacity (FVC) measured in mL
measured At Week 52
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed